The Impact Of Biogen Alzheimer's Drug FDA Approval
Schwab Network
English - June 16, 2021 21:17 - 6 minutes - 29.5 MB - ★★★★★ - 23 ratingsNews Commentary News Business News business news news commentary news Homepage Download Apple Podcasts Google Podcasts Overcast Castro Pocket Casts RSS feed
Previous Episode: Arbor Realty Trust (ABR) In A Strong Housing Market
Next Episode: The Fed's Latest Comments
The FDA has approved Biogen’s (BIIB) Alzheimer’s drug. Brad Loncar, CEO of Loncar Investments, talks about the impact of the Biogen drug approval as well as the recent activity in the health care sector. He also discusses how Biogen’s treatment compares to others in the pipeline and what he believes is the next catalyst in the health care sector. Tune in to find out more.